Landscape Capital Management L.L.C. Buys New Shares in Haleon plc (NYSE:HLN)

Landscape Capital Management L.L.C. acquired a new stake in Haleon plc (NYSE:HLN - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 169,531 shares of the company's stock, valued at approximately $1,794,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sculptor Capital LP lifted its holdings in Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company's stock worth $73,407,000 after buying an additional 3,592,000 shares in the last quarter. Clearbridge Investments LLC lifted its stake in Haleon by 8.6% in the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company's stock valued at $344,888,000 after buying an additional 3,307,009 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Haleon by 95.5% during the second quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company's stock valued at $16,143,000 after purchasing an additional 954,622 shares during the period. Natixis Advisors LLC lifted its holdings in Haleon by 142.5% during the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company's stock worth $15,593,000 after acquiring an additional 866,070 shares in the last quarter. Finally, Raymond James & Associates increased its stake in Haleon by 14.7% during the 2nd quarter. Raymond James & Associates now owns 4,019,978 shares of the company's stock worth $33,205,000 after purchasing an additional 515,651 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

HLN traded up $0.10 during trading hours on Friday, hitting $9.65. The stock had a trading volume of 7,504,641 shares, compared to its average volume of 5,303,902. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a market cap of $43.68 billion, a PE ratio of 28.38, a price-to-earnings-growth ratio of 2.86 and a beta of 0.30. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The company's fifty day simple moving average is $10.03 and its 200 day simple moving average is $9.37.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. The Goldman Sachs Group cut shares of Haleon from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. UBS Group raised shares of Haleon to a "strong-buy" rating in a report on Tuesday, October 1st. Berenberg Bank initiated coverage on shares of Haleon in a research note on Tuesday, August 6th. They issued a "buy" rating for the company. Finally, Morgan Stanley boosted their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.